Čeština | Dansk | Deutsch | English | Español | Français | Italiano | Nederlands | Norsk | Polski | Português | Pусский | Suomi | Svenska | US
Euro Huntington's disease network [logo]
EHDN2016 DISEASE NETWORK REGISTRY PROJECTS LOGIN
 
 
  
Neuroprotective Therapy - Meetings - Meeting September 2005 -
--->Uutiset
[-]Projekti
--->Rahoittaja
--->[-]Johtokunta
--->Arnesen
--->Blumenstein
--->Burgunder
--->Craufurd
--->Humbert
--->Jones
--->Kremer
--->Reilmann
--->Roos
--->Rosser
--->Weydt
--->Capper-Loup
--->Feihle
--->Levey
--->McLean
--->Julkiset asiakirjat
--->[+]Writing Committee Strategic ...
--->[+]Neuvoa antava lautakunta
--->Keskuskoordinaatio
--->Kielikoordinaatio
--->Fellowship Programme
--->[-]Perustuslaki 2008
--->Article 1
--->Article 2
--->Article 3
--->Article 4
--->Article 5
--->Article 6
--->Article 7
--->Article 8
--->Article 9
--->Article 10
--->Article 11
--->Article 12
--->Documents
--->[+]Äänestys
--->[-]Jäsenet
--->Jäsenyyden hakeminen
[+]Tutkimuspaikat
[-]Työryhmät
--->[+]Advanced HD
--->[+]Behavioural Phenotype
--->[+]Biological Modifiers
--->[+]Biomarkers
--->[+]Brainbanking
--->[+]Cognitive Phenotype
--->[+]Environmental Modifiers
--->[+]Functional Ability
--->[+]Genetic Testing
--->[+]Genetic Modifiers
--->[+]Health Economics
--->[+]Imaging
--->[+]Juveniili Huntingtonin tauti
--->[+]Motor Phenotype
--->[-]Neuroprotective Rx
--->[+]Päivämäärät
--->[-]Meetings
--->Meeting 2005/01
--->Meeting 2005/09
--->Meeting 2008/09
--->Meeting 2009
--->[-]Physiotherapy
--->Dates
--->[+]Meetings
--->[+]Quality of Life
--->[+]Standard of Care
--->[+]Surgical Therapy
--->[+]Symptomatic Rx
--->[+]Young Adults
[-]Tapahtumat
--->[-]EHDN 2016
--->Announcement
--->Introduction
--->Registration
--->Programme Fri
--->Programme Sat
--->Programme Sun
--->Additional Meetings
--->Floor plan
--->[+]Overduin Registration
--->CME points
--->Sponsoring
--->Travel Information
--->Hotel booking
--->Social activities
--->Reimbursement
--->[+]Abstract Submission
--->Contacts
--->Documents
--->Feedback
--->EHDN 2014
--->[-]EHDN 2012
--->Introduction
--->Announcement
--->Programme Fri
--->Programme Sat
--->Programme Sun
--->Additional Meetings
--->Important Dates
--->Registration
--->[+]Travel & Accommodation
--->[+]EHA Registration
--->EHA Programme
--->Reception Dinner
--->About Stockholm
--->[+]Abstract Submission
--->Reimbursement
--->[+]Documents
--->Contacts
--->Feedback & Evaluation
--->[+]EHDN 2010
--->[-]EHDN 2008
--->Programme
--->Additional Meetings
--->EHA Programme
--->Social Programme
--->Kids Programme
--->Important Dates
--->Voting
--->Reimbursement
--->[+]Registration
--->[+]Abstract Submission
--->Evaluation & Feedback
--->[+]Travel and Location
--->[+]About Lisbon
--->[+]Documents
--->Committees
--->Contact
--->[+]EHDN 2007
--->[+]EHDN 2006
--->[-]EHDN 2005
--->Final Programme
--->Plenary Dinner
--->Registration
--->Working Groups
--->Meeting Venue
--->Manchester
--->Evaluation & Feedback
--->[+]EHDN 2004
[+]Yhteydenpito
--->Työtarjoukset

Meeting in Manchester, 9th September 2005

  1. Final discussion on drug scoring:
    • Is there agreement on scoring criteria?
    • Is the impact of each criterion on the final drug score appropriate?
    • Is the score for each drug appropriate?
    • Do the final drug scores reflect our thinking about the drugs?
    • Have we forgotten any important drug?
  2. Conclusions and suggestions for EHDN
    • Is there a drug or mechanism that we can recommend for clinical trial?
    • If yes: what kind of trial?
    • If no: what are the criteria/requirements that need to be fulfilled to get into clinical trials
  3. Next steps for the working group
    • How do we want to update our drug scoring in the future?
    • Do we want to proceed into an investigator initiated trial?
    • Do we want to get pharmaceutical industry interested in running trials? If so, how do we want to establish this and what kind of trial would be our favourite to realize?
    • Further suggestions by open discussion with all the working group members
  
about us | privacy statement | disclaimer | terms of use